Vaginal Injection of Platelet Rich Plasma for Sexual Function
NCT ID: NCT05769283
Last Updated: 2025-10-22
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
NA
Total Enrollment
52 participants
Study Classification
INTERVENTIONAL
Study Start Date
2023-08-18
Study Completion Date
2025-03-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The goal of this clinical trial is to learn about an injection of platelet rich plasma into the vaginal wall and around the clitoris. The main questions it aims to answer are:
* To see if a PRP injection improves sexual satisfaction
* To learn the effect of PRP injections on sexual function Participants will get assigned to getting a one time PRP injection or a placebo injection. They will answer questionnaires about their sexual function at their first visit and their followup visit. The investigators will then compare the two groups.
* To see if a PRP injection improves sexual satisfaction
* To learn the effect of PRP injections on sexual function Participants will get assigned to getting a one time PRP injection or a placebo injection. They will answer questionnaires about their sexual function at their first visit and their followup visit. The investigators will then compare the two groups.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Regenerative Treatment of Female Genital Atrophy
NCT07306611
Vulvo Vaginal Atrophy
COMPLETED
PHASE1/PHASE2
Assessing the Effects of a Topically Applied Cream to Clitoral Blood Flow
NCT01085981
Female Sexual Dysfunction
UNKNOWN
NA
The Impact of a Topical Vasodilating Cream on Female Sexual Experience
NCT01078077
Female Sexual Dysfunction
UNKNOWN
A Multicenter, Open-Label, Non-Comparative Study of the Safety and Contraceptive Efficacy of the Woman's Condom
NCT01223313
Contraception
COMPLETED
PHASE3
Safety and Efficacy of Vaginal Microbiota Transplant (VMT) in Women With Bacterial Vaginosis (BV)
NCT03769688
Bacterial Vaginosis
WITHDRAWN
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Platelet-rich plasma is a substance derived from the participants' own blood and is not considered a drug. It is created through centrifugation of a participant's whole blood to separate out red blood cells leaving a concentrated plasma product containing the participant's natural endogenous growth factors and cytokines. PRP has been studied and found to be effective and safe without serious side effects in specialties such as orthopedics and dermatology. It is unclear if PRP injections to the anterior vaginal wall and clitoris improves sexual function and stress urinary incontinence. To date, the only literature on this is a single arm unblinded study.
This will be a single-blinded randomized controlled trial. Our primary objective is to determine if platelet rich plasma (PRP) injections into the anterior vaginal wall and periclitoral tissues boosts sexual satisfaction in sexually active women without a history of female sexual dysfunction (FSD). Our secondary objective is to determine the effect of PRP injections on sexual function. Qualifying subjects will be randomized 1:1 in permutated blocks to receive either PRP injection or placebo control (sterile saline injection). They will be followed for 6 month in the following fashion:
Visit #1: Screening, Baseline \& Enrollment (virtual visit) This visit will be done virtually. Premenopausal sexually-active women meeting the listed inclusion criteria and exclusion criteria will view a short powerpoint orienting them to the research study and offer background about PRP and its proposed benefit for sexual function. Afterwards, a research team member will review the study and informed consent form, answer any questions, and, if they are interested in participating, the coordinator will obtain verbal informed consent and document verbal consent, and enroll the subject. The subject will then be asked to complete a series of questionnaires.
Visit #2: Randomization \& Intervention (in-person visit) Subjects attending the in-person second visit will sign the informed consent form and then be randomized to either intervention (PRP) injection or placebo (injectable saline). The subject will be blinded to the treatment allocation.
\- Blinding: This is a single-blinded study. The subject will not know whether they are giving or receiving PRP. The injector will be aware. The code will be broken only after the study is complete. At this point all the research team will be made aware of the results. During the study, the blinding may be broken only in emergencies when knowledge of the subject's treatment group is necessary for further subject management. When possible, the Investigator will discuss the emergency with the monitor (the IRB) prior to unblinding.
The unblinded research staff will complete the randomization in REDCap to obtain the treatment assignment. The subject will then undergo a venipuncture and 40 ml of blood will be obtained. If assigned to intervention, the blood sample will be centrifuged for 15 minutes and spun down according to the PRP kit preparation protocol for the Arthrex Angel system by trained and experienced research staff. On average, 2-4 cc of leukocyte-rich PRP is produced per 40 cc of whole blood. If assigned to the placebo arm, the blood sample will be properly disposed and the patient will receive 4 cc of injectable saline.
Injections will be performed as follows using a 25 gauge needle by a trained licensed provider with medical staff support. After positioning the patient and applying topical lidocaine to the vagina (applied for a minimum of 10 minutes), the vaginal tissues will be prepped and a total of 2-4 cc of allocated treatment will be injected into the distal anterior vaginal wall approximately 3 cm from the urethral meatus and in the peri-clitoral region. This injection will be superficial and just deep to the vaginal epithelium.
Visit #3 Follow-up (4 weeks +/- 7 days via virtual visit) The subject will complete the baseline questionnaire plus some additional questions. The subject will be asked about any AEs. This visit will be conducted virtually.
Visit #4 Follow-up (6 months +/- 14 days via virtual visit) The subject will complete the same questionnaire as in Visit #3. The subject will be asked about any AEs. This visit will be conducted virtually, unless the subject requests to be seen in person.
The data collected during the study will include the subjects' responses to validated questionnaires regarding sexual health/function. Basic demographic information will be collected at the first visit. These data will be obtained via an online survey and stored in a secure REDCap database.
Overall expected risks are anticipated to be rare in occurrence given no reported adverse reactions after vaginal PRP injections. Anticipated and known risks will be disclosed to the participants via the informed consent process. All study participants will be closely monitored for adverse events and at 50% enrollment a safety monitor will review all AE and safety data. All study investigators will receive training on the study protocol and AE monitoring.
An adverse event (AE) will be defined as any unfavorable or unintended symptom or sign, temporarily associated with an investigational intervention during the conduct of a clinical trial. Pre-existing diseases or conditions will not be considered AEs unless there is an increase in the frequency or severity, or change in the quality, of the disease or condition. Events that occur in patients treated with placebo will also be considered AEs. AEs will be recorded and serious adverse events will be considered an adverse events that either: (1) results in death, (2) is life threatening, (3) requires inpatient hospitalization, (4) results in permanent or significant disability or incapacity, or (5) is another medically important condition. All serious adverse events will be reported to the MedStar Health Research Institute (MHRI) IRB during which time study enrollment will be stopped and the safety monitor will conduct a review to assess safety of study continuation.
The investigators plan to recruit women via social media and in MedStar women's health clinics. For social media, the investigators will post the flyer on the local Facebook "Mom Group" pages. The investigators plan to post flyers in the waiting room and restrooms of the clinics. The investigators will post the flyers in the break rooms at MedStar Washington Hospital Center. Participants may also be referred by their clinical provider. Once they have expressed interest in the study, a member of the research team will contact them to screen for eligibility and discuss the study in detail. The investigators plan to recruit 52 participants.
Our sample size achieves 80% power to detect non-inferiority using a one-sided t test with significance level of 0.025. It is assumed that the true difference between the means is 0, standard deviation of the mean difference (mean score at 6 week follow up minus mean score at baseline) for both groups are considered to be 2.5 and 1.5 (based on previous studies of FSFI), and margin of non-inferiority is -1.8. This would be achieved with a sample size of 23 per treatment arm. Factoring in a dropout rate of 10%, each treatment arm will be 26 participants.
Statistical analysis will be by intent-to-treat. Comparisons will be performed using a t-test for continuous variables and chi-square or fischers exact for categorical variables as appropriate. The investigators will use different variables to determine if there are any significant associations using a univariate analysis that can be entered into a multiple logistic regression model, which will allow for the determination of independent predictors of outcome variables.
This will be a single-blinded randomized controlled trial. Our primary objective is to determine if platelet rich plasma (PRP) injections into the anterior vaginal wall and periclitoral tissues boosts sexual satisfaction in sexually active women without a history of female sexual dysfunction (FSD). Our secondary objective is to determine the effect of PRP injections on sexual function. Qualifying subjects will be randomized 1:1 in permutated blocks to receive either PRP injection or placebo control (sterile saline injection). They will be followed for 6 month in the following fashion:
Visit #1: Screening, Baseline \& Enrollment (virtual visit) This visit will be done virtually. Premenopausal sexually-active women meeting the listed inclusion criteria and exclusion criteria will view a short powerpoint orienting them to the research study and offer background about PRP and its proposed benefit for sexual function. Afterwards, a research team member will review the study and informed consent form, answer any questions, and, if they are interested in participating, the coordinator will obtain verbal informed consent and document verbal consent, and enroll the subject. The subject will then be asked to complete a series of questionnaires.
Visit #2: Randomization \& Intervention (in-person visit) Subjects attending the in-person second visit will sign the informed consent form and then be randomized to either intervention (PRP) injection or placebo (injectable saline). The subject will be blinded to the treatment allocation.
\- Blinding: This is a single-blinded study. The subject will not know whether they are giving or receiving PRP. The injector will be aware. The code will be broken only after the study is complete. At this point all the research team will be made aware of the results. During the study, the blinding may be broken only in emergencies when knowledge of the subject's treatment group is necessary for further subject management. When possible, the Investigator will discuss the emergency with the monitor (the IRB) prior to unblinding.
The unblinded research staff will complete the randomization in REDCap to obtain the treatment assignment. The subject will then undergo a venipuncture and 40 ml of blood will be obtained. If assigned to intervention, the blood sample will be centrifuged for 15 minutes and spun down according to the PRP kit preparation protocol for the Arthrex Angel system by trained and experienced research staff. On average, 2-4 cc of leukocyte-rich PRP is produced per 40 cc of whole blood. If assigned to the placebo arm, the blood sample will be properly disposed and the patient will receive 4 cc of injectable saline.
Injections will be performed as follows using a 25 gauge needle by a trained licensed provider with medical staff support. After positioning the patient and applying topical lidocaine to the vagina (applied for a minimum of 10 minutes), the vaginal tissues will be prepped and a total of 2-4 cc of allocated treatment will be injected into the distal anterior vaginal wall approximately 3 cm from the urethral meatus and in the peri-clitoral region. This injection will be superficial and just deep to the vaginal epithelium.
Visit #3 Follow-up (4 weeks +/- 7 days via virtual visit) The subject will complete the baseline questionnaire plus some additional questions. The subject will be asked about any AEs. This visit will be conducted virtually.
Visit #4 Follow-up (6 months +/- 14 days via virtual visit) The subject will complete the same questionnaire as in Visit #3. The subject will be asked about any AEs. This visit will be conducted virtually, unless the subject requests to be seen in person.
The data collected during the study will include the subjects' responses to validated questionnaires regarding sexual health/function. Basic demographic information will be collected at the first visit. These data will be obtained via an online survey and stored in a secure REDCap database.
Overall expected risks are anticipated to be rare in occurrence given no reported adverse reactions after vaginal PRP injections. Anticipated and known risks will be disclosed to the participants via the informed consent process. All study participants will be closely monitored for adverse events and at 50% enrollment a safety monitor will review all AE and safety data. All study investigators will receive training on the study protocol and AE monitoring.
An adverse event (AE) will be defined as any unfavorable or unintended symptom or sign, temporarily associated with an investigational intervention during the conduct of a clinical trial. Pre-existing diseases or conditions will not be considered AEs unless there is an increase in the frequency or severity, or change in the quality, of the disease or condition. Events that occur in patients treated with placebo will also be considered AEs. AEs will be recorded and serious adverse events will be considered an adverse events that either: (1) results in death, (2) is life threatening, (3) requires inpatient hospitalization, (4) results in permanent or significant disability or incapacity, or (5) is another medically important condition. All serious adverse events will be reported to the MedStar Health Research Institute (MHRI) IRB during which time study enrollment will be stopped and the safety monitor will conduct a review to assess safety of study continuation.
The investigators plan to recruit women via social media and in MedStar women's health clinics. For social media, the investigators will post the flyer on the local Facebook "Mom Group" pages. The investigators plan to post flyers in the waiting room and restrooms of the clinics. The investigators will post the flyers in the break rooms at MedStar Washington Hospital Center. Participants may also be referred by their clinical provider. Once they have expressed interest in the study, a member of the research team will contact them to screen for eligibility and discuss the study in detail. The investigators plan to recruit 52 participants.
Our sample size achieves 80% power to detect non-inferiority using a one-sided t test with significance level of 0.025. It is assumed that the true difference between the means is 0, standard deviation of the mean difference (mean score at 6 week follow up minus mean score at baseline) for both groups are considered to be 2.5 and 1.5 (based on previous studies of FSFI), and margin of non-inferiority is -1.8. This would be achieved with a sample size of 23 per treatment arm. Factoring in a dropout rate of 10%, each treatment arm will be 26 participants.
Statistical analysis will be by intent-to-treat. Comparisons will be performed using a t-test for continuous variables and chi-square or fischers exact for categorical variables as appropriate. The investigators will use different variables to determine if there are any significant associations using a univariate analysis that can be entered into a multiple logistic regression model, which will allow for the determination of independent predictors of outcome variables.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Sexual Behavior
Sexual Activity
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
SUPPORTIVE_CARE
Blinding Strategy
SINGLE
Participants
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Platelet Rich Plasma
Platelet Rich Plasma Injection
Group Type
ACTIVE_COMPARATOR
Platelet Rich Plasma
Intervention Type
OTHER
Platelet rich plasma (PRP) is autologous blood which has been centrifuged to separate the supernatant resulting in a solution with high concentration of platelets. It is then injected into the anterior vaginal wall and periclitoral area
Saline
Placebo injection of saline
Group Type
PLACEBO_COMPARATOR
Saline
Intervention Type
OTHER
Normal Saline to be injected into the anterior vaginal wall and periclitoral area
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Platelet Rich Plasma
Platelet rich plasma (PRP) is autologous blood which has been centrifuged to separate the supernatant resulting in a solution with high concentration of platelets. It is then injected into the anterior vaginal wall and periclitoral area
Intervention Type
OTHER
Saline
Normal Saline to be injected into the anterior vaginal wall and periclitoral area
Intervention Type
OTHER
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
O Shot
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Menarchal women (assigned female at birth)
* Age ≥ 18 years of age and \<51
· Sexually active with at least one episode of sexual activity per week defined as follows:
* Partnered or solo penetrative or non-penetrative stimulation of the clitoris or vagina
* English-speaking
* Willingness and ability to comply with the study requirements
* Age ≥ 18 years of age and \<51
· Sexually active with at least one episode of sexual activity per week defined as follows:
* Partnered or solo penetrative or non-penetrative stimulation of the clitoris or vagina
* English-speaking
* Willingness and ability to comply with the study requirements
Exclusion Criteria
* Pregnancy
* Pelvic organ prolapse (defined as symptomatic prolapse protruding beyond the hymen)
* History of prior vaginal mesh or midurethral mesh sling surgery
* History of pelvic radiation
* History of or diagnosis of chronic pelvic pain
* History of female genital mutilation
* History of prolapse or incontinence surgery
* History of genital tract malignancy
* Pelvic organ prolapse (defined as symptomatic prolapse protruding beyond the hymen)
* History of prior vaginal mesh or midurethral mesh sling surgery
* History of pelvic radiation
* History of or diagnosis of chronic pelvic pain
* History of female genital mutilation
* History of prolapse or incontinence surgery
* History of genital tract malignancy
Minimum Eligible Age
18 Years
Maximum Eligible Age
50 Years
Eligible Sex
FEMALE
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
SHE Foundation
OTHER
Sponsor Role
collaborator
Medstar Health Research Institute
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alexis Dieter, MD
Role: PRINCIPAL_INVESTIGATOR
Medstar Health Research Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
MedStar Lafayette Center
Washington D.C., District of Columbia, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Price DD, McGrath PA, Rafii A, Buckingham B. The validation of visual analogue scales as ratio scale measures for chronic and experimental pain. Pain. 1983 Sep;17(1):45-56. doi: 10.1016/0304-3959(83)90126-4.
Reference Type
BACKGROUND
Alves R, Grimalt R. A Review of Platelet-Rich Plasma: History, Biology, Mechanism of Action, and Classification. Skin Appendage Disord. 2018 Jan;4(1):18-24. doi: 10.1159/000477353. Epub 2017 Jul 6.
Reference Type
RESULT
Kramer ME, Keaney TC. Systematic review of platelet-rich plasma (PRP) preparation and composition for the treatment of androgenetic alopecia. J Cosmet Dermatol. 2018 Oct;17(5):666-671. doi: 10.1111/jocd.12679. Epub 2018 May 22.
Reference Type
RESULT
Xie X, Zhang C, Tuan RS. Biology of platelet-rich plasma and its clinical application in cartilage repair. Arthritis Res Ther. 2014 Feb 25;16(1):204. doi: 10.1186/ar4493.
Reference Type
RESULT
Elghblawi E. Platelet-rich plasma, the ultimate secret for youthful skin elixir and hair growth triggering. J Cosmet Dermatol. 2018 Jun;17(3):423-430. doi: 10.1111/jocd.12404. Epub 2017 Sep 8.
Reference Type
RESULT
Sukgen G, Ellibes Kaya A, Karagun E, Caliskan E. Platelet-rich plasma administration to the lower anterior vaginal wall to improve female sexuality satisfaction. Turk J Obstet Gynecol. 2019 Dec;16(4):228-234. doi: 10.4274/tjod.galenos.2019.23356. Epub 2020 Feb 28.
Reference Type
RESULT
Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, Ferguson D, D'Agostino R Jr. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000 Apr-Jun;26(2):191-208. doi: 10.1080/009262300278597.
Reference Type
RESULT
Derogatis LR, Rosen R, Leiblum S, Burnett A, Heiman J. The Female Sexual Distress Scale (FSDS): initial validation of a standardized scale for assessment of sexually related personal distress in women. J Sex Marital Ther. 2002 Jul-Sep;28(4):317-30. doi: 10.1080/00926230290001448.
Reference Type
RESULT
Srikrishna S, Robinson D, Cardozo L. Validation of the Patient Global Impression of Improvement (PGI-I) for urogenital prolapse. Int Urogynecol J. 2010 May;21(5):523-8. doi: 10.1007/s00192-009-1069-5. Epub 2009 Dec 15.
Reference Type
RESULT
Wiegel M, Meston C, Rosen R. The female sexual function index (FSFI): cross-validation and development of clinical cutoff scores. J Sex Marital Ther. 2005 Jan-Feb;31(1):1-20. doi: 10.1080/00926230590475206.
Reference Type
RESULT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STUDY00005761
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Vaginal Film Administration and Placement Study: FLAG
NCT02908503
COMPLETED
NA
Multi-Center Study of New Medications to Treat Vaginal Infections
NCT02308046
COMPLETED
PHASE3
Prospective on Market Patient-reported Outcomes for Milli
NCT06397885
ACTIVE_NOT_RECRUITING
Multi-Center Study of New Medications to Treat Vaginal Infections
NCT02308033
COMPLETED
PHASE3
Evaluation of the Efficacy and Safety of the Dermal Filler for Female Intimate Area Hydration and Atrophy of the Vagina.
NCT04659668
COMPLETED
NA
Assessing the Disintegration, Safety, and Acceptability of Placebo Vaginal Inserts for the Delivery of Vaginal Products
NCT02534779
COMPLETED
NA
Vaginal Microbiota, and STI/HIV Risk Among Adolescent Girls and Young Women
NCT03196492
COMPLETED
Evaluation of a Postcoital Sponge on Self-Reported Vaginal Health Parameters
NCT06530186
NOT_YET_RECRUITING
NA
Preliminary Study of a Vaginal Lubrication Ring to Treat the Symptoms of Vaginal Dryness
NCT02029053
COMPLETED
EARLY_PHASE1
Topical Ketotifen 0.25% for Secondary Vestibulodynia
NCT07257029
NOT_YET_RECRUITING
PHASE2
Vaginal Flora for Treatment of Bacterial Vaginosis
NCT02236429
ACTIVE_NOT_RECRUITING
NA
In-Home Use Study to Evaluate Use of an Intimate Health Product in Females
NCT00778934
COMPLETED
NA
Effectiveness and Safety of a Water-based and a Silicone-based Personal Lubricants With Sensory Action
NCT05644444
COMPLETED
NA
VIBRating vs Traditional Therapy for Treatment of ENTry Dyspareunia
NCT06840314
RECRUITING
NA
Effects of Vaginal Oxytocin Gel on Vaginal Cytologic Parameters in Postmenopausal Woman
NCT05627791
TERMINATED
PHASE2/PHASE3
The Novel Electrolyzed Water Spray Treatment the Genital Itching
NCT05766930
COMPLETED
NA
LOVE Trial: Limits On Vaginal Intercourse After Mid-urEthral Sling
NCT04680897
COMPLETED
NA
Efficacy and Safety of MC2-25 Cream & Vehicle in Women With Vulvar Lichen Sclerosus (VLS)
NCT06132919
COMPLETED
PHASE2
Postcoital Testing of the SILCS Diaphragm
NCT00561613
COMPLETED
PHASE1
Study of Vaginal Dilator Use After Pelvic Radiotherapy
NCT00789893
COMPLETED
Exploring the Effects of an Intravaginal Lactic Acid Gel on the Vaginal Microbiome
NCT05753813
RECRUITING
EARLY_PHASE1
Dose Ranging Study of SPL7013 Gel for Treatment of Bacterial Vaginosis (BV)
NCT01201057
COMPLETED
PHASE2
MATRIX-002: Trial to Assess Acceptability and Safety of Two Placebo Vaginal Films
NCT06046053
COMPLETED
EARLY_PHASE1
Efficacy of VR101 as a Personal Lubricant
NCT04288752
COMPLETED
NA